Join
Live feed
·
PRReleasevia Quantisnow
Monopar Therapeutics Inc. logo

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

ByQuantisnow·Wall Street's wire, on your screen.
MNPR· Monopar Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MNPR (Monopar Therapeutics Inc.) and more on Quantisnow.